

CANCER
HAS NO BORDERS
NEITHER
DO WE

EXPLORE OUR LATEST CLINICAL DATA:
VISIT THE BOOTH



ELCC 2026 Industry Satellite Symposium

Collaborate to innovate in the MDT:
Unlocking the potential of immunotherapy
in resectable NSCLC

BeOne: Our Global Footprint

1,200+
researchers

~12,000
employees
globally

175+
clinical
trials

30,000+
patients
enrolled†

45+
countries
across 6
continents

Lung cancer remains the leading cause of cancer-related deaths worldwide.¹ At BeOne Medicines, we are deeply committed to changing this reality by advancing innovative therapies to bring hope to patients and families affected by lung cancer.

Friday, 27 March 2026 | 16:45 – 17:45 (CET)
Auditorium D2, Bella Center Copenhagen, Copenhagen, Denmark



Chair

Martin Sebastian

University Hospital Frankfurt,
Germany

16:45–17:05

How do advances in the
treatment landscape
inform treatment selection?

Followed by Q&A

Medical Oncologist



Speaker

Jean Y Perentes

Lausanne University Hospital,
Switzerland

17:05–17:20

How do the latest
data inform the
surgical approach?

Followed by Q&A

Thoracic Surgeon



Speaker

Umberto Malapelle

University of Naples Federico II,
Italy

17:20–17:35

Which key factors may
inform the de-escalation/
escalation of treatment?

Followed by Q&A

Pathologist



MDT perspectives: How may the optimal treatment approach evolve in the future?

17:35–17:45

All faculty

† includes investigator-initiated trials
1. Bray F et al. *CA Cancer J Clin.* 2024;74(3):229–263.